Dr. Todd M. Bauer, MD
Hematology & Oncology (Hematology & Oncology Physician)
- Medicare participating
At a glance
- Medical school
- Loyola University of Chicago, Stritch School of Medicine (2005)
- Years since graduation
- 21
- In the NPI registry since
- 2007
- Medicare patients seen, 2024
- 559
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2005Medical school: Loyola University of Chicago, Stritch School of Medicine
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
TN license 41849
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Ascension Saint Thomas Hospital Nashville, TN
- Williamson Medical Center Franklin, TN
Medical groups
- Tennessee Oncology PLLC (358 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 559
- Services billed
- 184,864
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Injection, ferric carboxymaltose, 1 mg | 88,500 | 63 |
| Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 31,740 | 37 |
| Injection, nivolumab, 1 mg | 29,280 | 12 |
| Injection, paclitaxel, 1 mg | 7,092 | 11 |
| Injection, denosumab, 1 mg | 5,400 | 33 |
| Injection, dexamethasone sodium phosphate, 1 mg | 2,936 | 60 |
| Injection, rituximab-arrx, biosimilar, (riabni), 10 mg | 2,010 | 12 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 1,704 | 377 |
| Insertion of needle into vein for collection of blood sample | 1,651 | 381 |
| Blood test, comprehensive group of blood chemicals | 1,381 | 375 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Prednisone Other prescribers in Nashville, TN | 93 |
| Anastrozole Other prescribers in Nashville, TN | 93 |
| Eliquis (apixaban) Other prescribers in Nashville, TN | 63 |
| Revlimid (lenalidomide) | 62 |
| Dexamethasone Other prescribers in Nashville, TN | 62 |
| Acyclovir Other prescribers in Nashville, TN | 61 |
| Hydroxyurea Other prescribers in Nashville, TN | 61 |
| Prochlorperazine Maleate Other prescribers in Nashville, TN | 58 |
| Abiraterone Acetate | 47 |
| Orgovyx (relugolix) | 40 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 31 companies reported 68 payments worth $26,207 in total to this clinician.
| Pfizer Inc. | $20,021 |
|---|---|
| Bayer HealthCare Pharmaceuticals Inc. | $4,408 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $196 |
| Regeneron Healthcare Solutions, Inc. | $177 |
| Kite Pharma, Inc. | $147 |
| Adc Therapeutics America, Inc. | $131 |
| Sobi, Inc | $125 |
| Novartis Pharmaceuticals Corporation | $120 |
| Consulting Fee | $13,373 |
|---|---|
| Compensation for services other than consulting (speaking, faculty) | $11,000 |
| Food and Beverage | $1,834 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Pfizer Inc. Jan 15, 2025 | Compensation for services other than consulting (speaking, faculty) LORBRENA · ONCOLOGY | $7,300 |
| Pfizer Inc. Aug 4, 2025 | Consulting Fee LORBRENA · ONCOLOGY | $6,037 |
| Pfizer Inc. Jul 5, 2025 | Compensation for services other than consulting (speaking, faculty) VIZIMPRO; LORBRENA; XALKORI · ONCOLOGY · in-kind Company’s descriptionNo payment was made directly to this author. This is a fair market value payment for editorial or medical writing services paid to a 3rd-party vendor to assist with the development of a publication. | $3,700 |
| Bayer HealthCare Pharmaceuticals Inc. Sep 17, 2025 | Consulting Fee Vitrakvi · Oncology | $2,184 |
| Bayer HealthCare Pharmaceuticals Inc. Sep 18, 2025 | Consulting Fee Vitrakvi · Oncology | $2,184 |
| Pfizer Inc. Dec 24, 2025 | Consulting Fee | $1,925 |
| Pfizer Inc. May 29, 2025 | Consulting Fee LORBRENA · ONCOLOGY | $755 |
| Pfizer Inc. Aug 15, 2025 | Consulting Fee LORBRENA · ONCOLOGY | $150 |
| Pfizer Inc. Aug 4, 2025 | Consulting Fee LORBRENA · ONCOLOGY | $123 |
| Pfizer Inc. May 29, 2025 | Consulting Fee LORBRENA · ONCOLOGY | $15.40 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $300 in research payments for these studies, mostly to the institutions running them.
- A phase II multicenter three cohort study of oral cMET inhibitor INC280 in adult patients with EGFR wild type wt advanced non small cell lung cancer NSCLC who have received one or two prior lines of systemic therapy f…
Novartis Pharmaceuticals Corporation
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.